Tyra Biosciences, Inc. $TYRA Shares Sold by BVF Inc. IL

BVF Inc. IL reduced its stake in shares of Tyra Biosciences, Inc. (NASDAQ:TYRA) by 41.7% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,127,665 shares of the company’s stock after selling 1,522,129 shares during the quarter. Tyra Biosciences comprises approximately 1.9% of BVF Inc. IL’s portfolio, making the stock its 19th largest holding. BVF Inc. IL’s holdings in Tyra Biosciences were worth $55,936,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors have also recently bought and sold shares of TYRA. Commodore Capital LP grew its position in shares of Tyra Biosciences by 226.3% during the second quarter. Commodore Capital LP now owns 3,100,000 shares of the company’s stock worth $29,667,000 after acquiring an additional 2,150,000 shares during the last quarter. Farallon Capital Management LLC raised its holdings in Tyra Biosciences by 80.7% during the fourth quarter. Farallon Capital Management LLC now owns 2,066,818 shares of the company’s stock worth $54,337,000 after purchasing an additional 923,000 shares in the last quarter. Caligan Partners LP raised its holdings in Tyra Biosciences by 266.8% during the third quarter. Caligan Partners LP now owns 696,825 shares of the company’s stock worth $9,749,000 after purchasing an additional 506,875 shares in the last quarter. Balyasny Asset Management L.P. grew its stake in shares of Tyra Biosciences by 139.8% during the 2nd quarter. Balyasny Asset Management L.P. now owns 583,386 shares of the company’s stock worth $5,583,000 after purchasing an additional 340,142 shares during the period. Finally, State Street Corp grew its stake in shares of Tyra Biosciences by 74.9% during the 4th quarter. State Street Corp now owns 749,463 shares of the company’s stock worth $19,703,000 after purchasing an additional 320,991 shares during the period. 84.14% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of analysts have commented on the company. JonesTrading assumed coverage on Tyra Biosciences in a research report on Wednesday. They set a “buy” rating and a $56.00 target price on the stock. Bank of America raised their price target on Tyra Biosciences from $37.00 to $42.00 and gave the stock a “buy” rating in a research note on Wednesday, June 10th. Canaccord Genuity Group initiated coverage on shares of Tyra Biosciences in a research note on Monday, April 6th. They set a “buy” rating and a $50.00 price target on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Tyra Biosciences in a research report on Monday, April 20th. Finally, HC Wainwright reissued a “buy” rating and issued a $45.00 price objective on shares of Tyra Biosciences in a research report on Thursday, May 14th. One analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Tyra Biosciences currently has an average rating of “Moderate Buy” and an average price target of $47.00.

Insider Buying and Selling

In other Tyra Biosciences news, Director Gilla Kaplan sold 14,295 shares of Tyra Biosciences stock in a transaction on Wednesday, March 25th. The shares were sold at an average price of $36.97, for a total value of $528,486.15. Following the completion of the transaction, the director owned 28,231 shares of the company’s stock, valued at $1,043,700.07. The trade was a 33.61% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this link. 12.50% of the stock is currently owned by corporate insiders.

Tyra Biosciences Stock Performance

NASDAQ:TYRA opened at $29.07 on Thursday. The business’s 50-day simple moving average is $33.04 and its 200 day simple moving average is $31.20. The stock has a market cap of $1.73 billion, a price-to-earnings ratio of -13.33 and a beta of 0.75. Tyra Biosciences, Inc. has a one year low of $8.98 and a one year high of $40.65.

Tyra Biosciences (NASDAQ:TYRA) last released its earnings results on Wednesday, May 13th. The company reported ($0.64) earnings per share for the quarter, missing the consensus estimate of ($0.60) by ($0.04). On average, equities research analysts predict that Tyra Biosciences, Inc. will post -2.69 EPS for the current year.

Tyra Biosciences Company Profile

Tyra Biosciences (NASDAQ: TYRA) is a clinical-stage precision oncology company focused on the discovery and development of small-molecule therapies for genetically defined cancers. The company integrates bioinformatics, molecular biology and medicinal chemistry to identify oncogenic drivers and design targeted inhibitors. By leveraging large-scale genomic datasets and functional screening, Tyra Biosciences aims to advance therapies that address patient populations with high unmet medical need.

The company’s pipeline includes multiple programs at various stages of development, each directed against distinct molecular vulnerabilities in cancer cells.